Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ASPEN-06 trial in HER2-positive gastric cancer - ...
The first-in-human phase 1/2 study of TSN1611, a highly selective KRAS G12D inhibitor, in patients with advanced solid tumors. Seizure-related homolog 6 (SEZ6) expression and ctDNA methylation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results